# A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

> **NCT02512237** · PHASE1 · TERMINATED · sponsor: **Zhejiang Medicine Co., Ltd.** · enrollment: 9 (actual)

## Conditions studied

- Breast Neoplasms
- Stomach Neoplasms

## Interventions

- **DRUG:** ARX788

## Key facts

- **NCT ID:** NCT02512237
- **Lead sponsor:** Zhejiang Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Replace with a new trial
- **Last updated:** 2020-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02512237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02512237, "A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02512237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*